These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
943 related articles for article (PubMed ID: 27531477)
21. Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells. Hu Y; Guo R; Wei J; Zhou Y; Ji W; Liu J; Zhi X; Zhang J Cell Death Dis; 2015 Dec; 6(12):e2020. PubMed ID: 26673665 [TBL] [Abstract][Full Text] [Related]
23. Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma. Kirstein MM; Boukouris AE; Pothiraju D; Buitrago-Molina LE; Marhenke S; Schütt J; Orlik J; Kühnel F; Hegermann J; Manns MP; Vogel A Liver Int; 2013 May; 33(5):780-93. PubMed ID: 23489999 [TBL] [Abstract][Full Text] [Related]
24. Hsa_circ_0000199 facilitates chemo-tolerance of triple-negative breast cancer by interfering with miR-206/613-led PI3K/Akt/mTOR signaling. Li H; Xu W; Xia Z; Liu W; Pan G; Ding J; Li J; Wang J; Xie X; Jiang D Aging (Albany NY); 2021 Jan; 13(3):4522-4551. PubMed ID: 33495420 [TBL] [Abstract][Full Text] [Related]
25. Effects of PI3K inhibitor NVP-BKM120 on acquired resistance to gefitinib of human lung adenocarcinoma H1975 cells. Liang YC; Wu HG; Xue HJ; Liu Q; Shi LL; Liu T; Wu G J Huazhong Univ Sci Technolog Med Sci; 2013 Dec; 33(6):845-851. PubMed ID: 24337846 [TBL] [Abstract][Full Text] [Related]
26. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells. Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279 [TBL] [Abstract][Full Text] [Related]
27. The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer. Bean JR; Hosford SR; Symonds LK; Owens P; Dillon LM; Yang W; Shee K; Schwartz GN; Marotti JD; Muller KE; Rosenkranz KM; Barth RJ; Chen VS; Agarwal VR; Miller TW Breast Cancer Res Treat; 2015 Jan; 149(1):69-79. PubMed ID: 25491778 [TBL] [Abstract][Full Text] [Related]
28. Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation. Al-Dhfyan A; Alhoshani A; Korashy HM Mol Cancer; 2017 Jan; 16(1):14. PubMed ID: 28103884 [TBL] [Abstract][Full Text] [Related]
29. Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors. Vandamme T; Beyens M; de Beeck KO; Dogan F; van Koetsveld PM; Pauwels P; Mortier G; Vangestel C; de Herder W; Van Camp G; Peeters M; Hofland LJ Br J Cancer; 2016 Mar; 114(6):650-8. PubMed ID: 26978006 [TBL] [Abstract][Full Text] [Related]
30. 20(S)-Protopanaxadiol-Induced Apoptosis in MCF-7 Breast Cancer Cell Line through the Inhibition of PI3K/AKT/mTOR Signaling Pathway. Zhang H; Xu HL; Wang YC; Lu ZY; Yu XF; Sui DY Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29614812 [TBL] [Abstract][Full Text] [Related]
31. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines. Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223 [TBL] [Abstract][Full Text] [Related]
32. High basal Wnt signaling is further induced by PI3K/mTor inhibition but sensitive to cSRC inhibition in mammary carcinoma cell lines with HER2/3 overexpression. Timmermans-Sprang EP; Gracanin A; Mol JA BMC Cancer; 2015 Jul; 15():545. PubMed ID: 26205886 [TBL] [Abstract][Full Text] [Related]
33. Cell type-specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors. Hsieh AC; Nguyen HG; Wen L; Edlind MP; Carroll PR; Kim W; Ruggero D Sci Signal; 2015 Nov; 8(403):ra116. PubMed ID: 26577921 [TBL] [Abstract][Full Text] [Related]
34. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression. Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823 [TBL] [Abstract][Full Text] [Related]
35. GOLPH3 inhibition reverses oxaliplatin resistance of colon cancer cells via suppression of PI3K/AKT/mTOR pathway. Yu T; An Q; Cao XL; Yang H; Cui J; Li ZJ; Xiao G Life Sci; 2020 Nov; 260():118294. PubMed ID: 32818544 [TBL] [Abstract][Full Text] [Related]
36. Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors. Chanal M; Chevallier P; Raverot V; Fonteneau G; Lucia K; Monteserin Garcia JL; Rachwan A; Jouanneau E; Trouillas J; Honnorat J; Auger C; Theodoropoulou M; Raverot G Mol Cancer Ther; 2016 Jun; 15(6):1261-70. PubMed ID: 26983879 [TBL] [Abstract][Full Text] [Related]
37. Differential modulation of PI3K/Akt/mTOR activity by EGFR inhibitors: A rationale for co-targeting EGFR and PI3K in cisplatin-resistant HNSCC. Liao J; Yang Z; Azarbarzin S; Cullen KJ; Dan H Head Neck; 2024 May; 46(5):1126-1135. PubMed ID: 38429897 [TBL] [Abstract][Full Text] [Related]
38. Inhibition of PI3K-Akt-mTOR signal pathway dismissed the stimulation of glucose on goose liver cell growth. Wei S; Han C; He F; Song Q; Kang B; Liu H; Li L; Xu H; Zeng X J Anim Physiol Anim Nutr (Berl); 2017 Oct; 101(5):e133-e143. PubMed ID: 27859698 [TBL] [Abstract][Full Text] [Related]
39. Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations. Park YL; Kim HP; Cho YW; Min DW; Cheon SK; Lim YJ; Song SH; Kim SJ; Han SW; Park KJ; Kim TY Int J Cancer; 2019 Jan; 144(2):389-401. PubMed ID: 29978469 [TBL] [Abstract][Full Text] [Related]
40. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38. Gohr K; Hamacher A; Engelke LH; Kassack MU BMC Cancer; 2017 Nov; 17(1):711. PubMed ID: 29100507 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]